FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Office of New Drugs RTF MAPP

[ Price : $8.95]

The CDER Office of New Drugs publishes a MAPP on the regulatory basis for refusing to file an NDA, sNDA, BLA, or sBLA.

FDA Publishes Drug Filing Checklists to Avoid Delays

[ Price : $8.95]

FDA publishes the checklists used by CDER reviewers to determine if an NDA or BLA can be accepted for filing.

Alector Scraps Dementia Drug After Missing Key Endpoint

[ Price : $8.95]

Alector discontinues development of latozinemab for treating a rare genetic form of frontotemporal dementia after a Phase 3 trial ...

CGMP Issues Seen in Foshan Records Review

[ Price : $8.95]

FDA warns Chinas Foshan Yiying Hygiene Products Co. about CGMP issues in its production of over-the-counter drugs.

QS Violations in Dongguan Rainbow Tech Inspection

[ Price : $8.95]

FDA warns Chinas Dongguan Rainbow Tech Electronic & Plastics Co. about Quality System Regulation violations in its manufacturing o...

Report on Ways to Cut Reliance on Foreign Drugs

[ Price : $8.95]

The Senate Special Committee on Aging releases a report with six recommendations for reducing the use of foreign-made drugs for se...

Makary Details DTC Enforcement Crackdown on Podcast

[ Price : $8.95]

FDA commissioner Marty Makary addresses during a podcast the agencys significant shift in enforcement policy directed at pha...

FDA Still Finding Issues at Nephron Pharmaceuticals

[ Price : $8.95]

A South Carolina newspaper reports that the latest FDA inspection at Nephron Pharmaceuticals found the company still has significa...

Moderna Quits CMV Vaccine After Phase 3 Failure

[ Price : $8.95]

Moderna stops the development of its congenital cytomegalovirus vaccine after it failed to meet the primary endpoint in a large Ph...

3rd Patient-Focused Drug Development Guidance

[ Price : $8.95]

FDA publishes the third in a series of guidances on aspects of collecting patient experience data to be used in medical product de...